Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Twelve to 35 months of age at enrollment.~* Minimum weight of 8 kg.~* In good health, as determined by parent/guardian verbal medical history and physical examination by clinical investigator.~* Parent/guardian available by telephone for safety data collection through 6 months post-dose 2.~* Ability of parent/guardian to understand and comply with the requirements of the protocol.~* Signed informed consent document and Health Insurance Portability and Accountability Act (HIPAA) authorization by the parent/guardian prior to performance of any study procedures.~Exclusion Criteria:~* History of hypersensitivity to any component of LAIV or TIV, including egg or egg products.~* History of hypersensitivity to gentamicin.~* Known or suspected immune deficiency diseases or immunosuppressed or have altered or compromised immune status as a consequence of treatment with immunosuppressive therapies.~* Known close contact with a severely immunocompromised person, such as someone currently in isolation secondary to a bone marrow transplantation (LAIV recipients should avoid close contact with severely immunocompromised individuals for at least 7 days after vaccination).~* History of chronic underlying medical conditions such as chronic disorders of the cardiovascular and pulmonary systems, chronic metabolic diseases (including diabetes), renal dysfunction, or hemoglobinopathies.~* History of Guillain-Barré syndrome.~* History of asthma or reactive airways disease.~* Acute febrile (\>99.6 degrees Fahrenheit axillary) and/or respiratory illness, within the 72 hours prior to enrollment.~* Use of aspirin or aspirin containing products in the month prior to enrollment or anticipated use during the study.~* Administration of any intranasal medication within 2 weeks prior to enrollment or expected receipt during this study.~* Previous receipt of an influenza vaccine.~* Administration of any live virus vaccine within 4 weeks prior to enrollment or (other than study vaccine) planned receipt of another live virus vaccine before completion of the 2 weeks after the last vaccination in this study\*~* Administration of any inactivated vaccine within 2 weeks prior to enrollment or planned receipt of another inactivated vaccine before 2 weeks after the last vaccination in this study\*~* Participation in another investigational trial or administration of any investigational drug within 1 month prior to enrollment or during this study.~* Any condition that in the opinion of the investigator would interfere with the interpretation or evaluation of the vaccine.~  * Routine immunizations can be resumed after the memory aid period following dose 2.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- Vaccine 1: TIV. Vaccine 2: TIV. (Type: ACTIVE_COMPARATOR): Vaccine 1: TIV. Vaccine 2: TIV.
- Vaccine 1: LAIV. Vaccine 2: TIV. (Type: EXPERIMENTAL): Vaccine 1: LAIV. Vaccine 2: TIV.
- Vaccine 1: LAIV. Vaccine 2: LAIV. (Type: EXPERIMENTAL): Vaccine 1: LAIV. Vaccine 2: LAIV.
- Vaccine 1: TIV. Vaccine 2: LAIV. (Type: EXPERIMENTAL): Vaccine 1: TIV. Vaccine 2: LAIV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete